文献速递眼底病与葡萄膜炎

口服司美替尼不负面影响小鼠实验性视网膜脱离中的光感受器存活

Oral Selumetinib Does Not Negatively Impact Photoreceptor Survival in Murine Experimental Retinal Detachment.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

本研究在小鼠实验性视网膜脱离模型中,每日给予临床相关剂量(10 mg/mL)的MEK抑制剂司美替尼,从造模前1天开始。结果显示司美替尼有效阻断Müller胶质细胞中pERK积聚并改变视网膜小胶质/巨噬细胞表型,但未增加光感受器TUNEL阳性或进一步降低ONL厚度。结论提示MEK抑制在视网膜脱离中不损害光感受器存活。

要点

  • 司美替尼阻断了脱离视网膜Müller胶质细胞中pERK的积聚。
  • 司美替尼未增加光感受器TUNEL阳性或进一步降低ONL厚度。
  • 司美替尼阻断了视网膜内小胶质/巨噬细胞Iba-1荧光强度增加及阿米巴样形态获得。

核心结论

  • 在实验性视网膜脱离中,司美替尼阻断Müller细胞pERK积聚并改变小胶质/巨噬细胞表型,但未改变光感受器存活。

研究设计与样本

  • C57BL/6小鼠通过视网膜下透明质酸注射建立视网膜脱离,司美替尼以10 mg/mL每日给药,从造模前1天开始。
  • 分析光感受器TUNEL和ONL厚度,并用免疫荧光评估pERK分布、GFAP积聚和Iba-1。

主要发现

  • pERK在脱离视网膜的Müller胶质细胞中积聚,司美替尼有效阻断该积聚。
  • 司美替尼在第1天未诱导浆液性视网膜脱离,且与对照相比未增加TUNEL阳性光感受器或进一步降低ONL厚度。
  • 视网膜胶质增生未改变,但司美替尼阻断了视网膜内小胶质/巨噬细胞Iba-1荧光强度增加及阿米巴样形态获得。

临床怎么用

  • 该结果与MEK抑制剂治疗期间出现暂时性视网膜脱离的患者相对较好的视力相一致。

局限性

  • 视网膜脱离时MEK抑制情况下,视网膜可能通过其他神经保护通路代偿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling is neuroprotective in some retinal damage models but its role in neuronal survival during retinal detachment (RD) is unclear. In addition, serous RDs are a prevalent side effect of MEK inhibitors (MEKi), blocking MAPK/ERK signaling for treatment of certain cancers. We tested the hypothesis that MEKi treatment in experimental RD would increase photoreceptor death. METHODS: The MEKi selumetinib was delivered daily to C57BL/6 mice at a clinically relevant dose (10 mg/mL) starting 1 day prior to creating RD with subretinal hyaluronic acid injection. Photoreceptor TUNEL and outer nuclear layer (ONL) thickness were analyzed. Phospho-ERK1/2 (pERK) distribution, glial fibrillary acidic protein (GFAP) accumulation, and Iba-1 (microglia/macrophages) were evaluated with immunofluorescence. RESULTS: pERK accumulated in the Müller glia in detached retinas, but this was effectively blocked by selumetinib. Selumetinib did not induce serous RDs at day 1 and did not increase TUNEL positive photoreceptors or further decrease ONL thickness compared to controls. Retinal gliosis was not altered, but selumetinib did block the increase in intraretinal microglia/macrophage Iba-1 fluorescence intensity and acquisition of amoeboid morphology. CONCLUSIONS: MAPK/ERK is neuroprotective in some retinal damage models; in RD, selumetinib blocked Müller pERK accumulation and changed the retinal microglia/macrophage phenotype but did not alter photoreceptor survival. This is consistent with the relatively good visual acuity seen in patients developing transient retinal detachments on MEK inhibitor therapy. Compensation by other neuroprotective pathways in the retina during retinal detachment may occur in the presence of MEK inhibition.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Cebulla CM, Kim B, George V, et al. Oral Selumetinib Does Not Negatively Impact Photoreceptor Survival in Murine Experimental Retinal Detachment. Invest Ophthalmol Vis Sci. 2019. PMID: 30682205. doi:10.1167/iovs.18-25405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。